دورية أكاديمية
أعرض في EDS

Association of antidepressant drug use with outcome of patients with glioblastoma.

التفاصيل البيبلوغرافية
العنوان: Association of antidepressant drug use with outcome of patients with glioblastoma.
المؤلفون: Seliger C; Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany., Oppong FB; EORTC Headquarters, Brussels, Belgium., Lefranc F; Department of Neurosurgery, Erasmus Hospital, Free University of Brussels, Brussels, Belgium., Chinot O; Aix-Marseille University, APHM, CNRS, INP, Institute of Neurophysiopathology, CHU Timone, Service de Neuro-Oncologie, Marseille, France., Stupp R; Malnati Brain Tumor Institute of the Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Nabors B; Department of Neurology and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA., Gorlia T; EORTC Headquarters, Brussels, Belgium., Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
مؤلفون مشاركون: EORTC Brain Tumor Group
المصدر: International journal of cancer [Int J Cancer] 2023 Apr 01; Vol. 152 (7), pp. 1348-1359. Date of Electronic Publication: 2022 Nov 17.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
مواضيع طبية MeSH: Glioblastoma*/drug therapy, Humans ; Antidepressive Agents/adverse effects ; Anticonvulsants/therapeutic use ; Fatigue
مستخلص: Depressive symptoms are common among patients with glioblastoma, but patients are often not treated with antidepressants. There is only limited evidence on the association of antidepressant drug use with survival in glioblastoma. We performed a pooled analysis of patients treated within the CENTRIC, CORE, AVAglio and ACT-IV trials to explore the relation of antidepressant drug use with progression-free (PFS) and overall survival (OS) at baseline, at the start of maintenance therapy and at the start of maintenance cycle 4. We further assessed the association of antidepressant drugs with seizure, cognition, fatigue and a diagnosis of depression. Among more than 1700 patients, we found no significant association between the use of antidepressants at baseline or at the start of maintenance therapy and PFS or OS. However, we found OS, but not PFS, to be significantly worse in patients using antidepressants at the start of maintenance cycle 4. After adjustment for antiepileptic drug use and despite showing a trend for increased risk, seizures were not significantly associated with antidepressant drug use, nor was there a change in mini mental state examination (MMSE) scores or fatigue by antidepressant drug use at baseline. However, there was a significant positive association between antidepressant use at the start of maintenance treatment and fatigue during maintenance treatment. The association of antidepressant use at the start of maintenance cycle 4 with inferior OS of glioblastoma patients requires independent confirmation and further study. Further prospective trials should evaluate efficacy, side effects and associations with outcome of antidepressants in glioblastoma.
(© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
References: Shi C, Lamba N, Zheng LJ, et al. Depression and survival of glioma patients: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;172:8-19.
Knudsen-Baas KM, Johannesen TB, Myklebust TA, et al. Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. J Neurooncol. 2018;140:739-748.
Rooney A, Grant R. Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database Syst Rev. 2013;5:CD006932.
Caudill JS, Brown PD, Cerhan JH, Rummans TA. Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the mayo clinic experience. Am J Clin Oncol. 2011;34:385-387.
Rooney A, Grant R. SSRIs may (or may not) be a safe treatment for depression in GBM. Am J Clin Oncol. 2012;35:100.
Gramatzki D, Rogers JL, Neidert MC, et al. Antidepressant drug use in glioblastoma patients: an epidemiological view. Neurooncol Pract. 2020;7:514-521.
Lefranc F, Pouleau HB, Rynkowski M, De Witte O. Voltage-dependent K+ channels as oncotargets in malignant gliomas. Oncotarget. 2012;3:516-517.
Martinez R, Stuhmer W, Martin S, et al. Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival. BMC Cancer. 2015;15:839.
Hayashi K, Michiue H, Yamada H, et al. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Sci Rep. 2016;6:23372.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231-1251.
Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1100-1108.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37-51.
Jeon SH, Kim SH, Kim Y, et al. The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun. 2011;413:311-317.
Higgins SC, Pilkington GJ. The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res. 2010;30:391-397.
Bielecka-Wajdman AM, Ludyga T, Machnik G, Golyszny M, Obuchowicz E. Tricyclic antidepressants modulate stressed mitochondria in glioblastoma multiforme cells. Cancer Control. 2018;25:1073274818798594.
Shchors K, Massaras A, Hanahan D. Dual targeting of the Autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-lethal autophagy and therapeutic benefit. Cancer Cell. 2015;28:456-471.
Zoga M, Oulis P, Chatzipanagiotou S, et al. Indoleamine 2,3-dioxygenase and immune changes under antidepressive treatment in major depression in females. In Vivo. 2014;28:633-638.
Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197-203.
Sordillo PP, Sordillo LA, Helson L. The kynurenine pathway: a primary resistance mechanism in patients with glioblastoma. Anticancer Res. 2017;37:2159-2171.
Bi J, Khan A, Tang J, et al. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021;37:109957.
Nabors LB, Fink KL, Mikkelsen T, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17:708-717.
Chinot OL, de La Motte RT, Moore N, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28:334-340.
Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373-1385.
Putter H, van Houwelingen HC. Understanding Landmarking and its relation with time-dependent Cox regression. Stat Biosci. 2017;9:489-503.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
Hao A, Huang J, Xu X. Anxiety and depression in glioma patients: prevalence, risk factors, and their correlation with survival. Ir J Med Sci. 2021;190:1155-1164.
Loppenthin K, Johansen C, Larsen MB, et al. Depressive symptoms in Danish patients with glioma and a cancer-free comparison group. J Natl Compr Canc Netw. 2020;18:1222-1229.
Litofsky NS, Farace E, Anderson F Jr, Meyers CA, Huang W, Laws ER Jr. Glioma outcomes project I. depression in patients with high-grade glioma: results of the glioma outcomes project. Neurosurgery. 2004;54:358-366. discussion 66-7, 367.
Anderson SI, Taylor R, Whittle IR. Mood disorders in patients after treatment for primary intracranial tumours. Br J Neurosurg. 1999;13:480-485.
Rooney AG, Carson A, Grant R. Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst. 2011;103:61-76.
Greenberg DB. Barriers to the treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004;2004:127-135.
Leykin Y, Dunn LB, Munoz RF. The effect of depression on the decision to join a clinical trial. J Consult Clin Psychol. 2017;85:751-756.
Brody DJ, Gu Q. Antidepressant use among adults: United States, 2015-2018. NCHS Data Brief. 2020;377:1-8.
Ryden I, Thurin E, Carstam L, et al. Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study. BMC Cancer. 2021;21:248.
Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry. 2015;15:315.
Detyniecki K. Do psychotropic drugs cause epileptic seizures? A review of the available evidence. Curr Top Behav Neurosci. 2022;55:267-279.
Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33:433-438.
Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009;7:331-336.
Pae CU, Marks DM, Patkar AA, Masand PS, Luyten P, Serretti A. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10:1561-1570.
Beevers Z, Hussain S, Boele FW, Rooney AG. Pharmacological treatment of depression in people with a primary brain tumour. Cochrane Database Syst Rev. 2020;7:CD006932.
Fu X, Wu C, Han N, et al. Depressive and anxiety disorders worsen the prognosis of glioblastoma. Aging (Albany NY). 2020;12:20095-20110.
Rosenblatt L, Block SD. Depression, decision making, and the cessation of life-sustaining treatment. West J Med. 2001;175:320-325.
Young K, Singh G. Biological mechanisms of cancer-induced depression. Front Psych. 2018;9:299.
Fu X, Zhang P, Song H, et al. LTBP1 plays a potential bridge between depressive disorder and glioblastoma. J Transl Med. 2020;18:391.
Song L, Quan X, Su L, et al. Inflammation and behavioral symptoms in preoperational glioma patients: is depression, anxiety, and cognitive impairment related to markers of systemic inflammation? Brain Behav. 2020;10:e01771.
Bekhbat M, Treadway MT, Goldsmith DR, et al. Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. Brain Behav Immun. 2020;88:161-165.
Starkweather AR, Sherwood P, Lyon DE, et al. Depressive symptoms and cytokine levels in serum and tumor tissue in patients with an astrocytoma: a pilot study. BMC Res Notes. 2014;7:423.
Feng G, Kang C, Yuan J, et al. Neuroendocrine abnormalities associated with untreated first episode patients with major depressive disorder and bipolar disorder. Psychoneuroendocrinology. 2019;107:119-123.
Han T, Zuo Z, Qu M, Zhou Y, Li Q, Wang H. Comprehensive analysis of inflammatory response-related genes, and prognosis and immune infiltration in patients with low-grade glioma. Front Pharmacol. 2021;12:748993.
Liu H, Sun Y, Zhang Q, et al. Pro-inflammatory and proliferative microglia drive progression of glioblastoma. Cell Rep. 2021;36:109718.
Yeo ECF, Brown MP, Gargett T, Ebert LM. The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cell. 2021;10:10.
Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero CH. Sex-specific differences in glioblastoma. Cell. 2021;10:10.
فهرسة مساهمة: Keywords: antidepressant drugs; glioblastoma; survival
سلسلة جزيئية: ClinicalTrials.gov NCT00689221; NCT00813943; NCT00943826; NCT01480479
المشرفين على المادة: 0 (Antidepressive Agents)
0 (Anticonvulsants)
تواريخ الأحداث: Date Created: 20221108 Date Completed: 20230202 Latest Revision: 20230303
رمز التحديث: 20240628
DOI: 10.1002/ijc.34344
PMID: 36346112
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0215
DOI:10.1002/ijc.34344